Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1979 2
1983 3
1984 1
1985 1
1986 2
1990 1
1993 1
1995 2
1997 1
1998 1
2000 4
2002 2
2003 2
2006 1
2007 2
2008 1
2009 1
2010 3
2011 5
2012 6
2013 7
2014 6
2015 8
2016 5
2017 6
2018 8
2019 7
2020 3
2021 8
2022 8
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity.
Alfares AA, Kelly MA, McDermott G, Funke BH, Lebo MS, Baxter SB, Shen J, McLaughlin HM, Clark EH, Babb LJ, Cox SW, DePalma SR, Ho CY, Seidman JG, Seidman CE, Rehm HL. Alfares AA, et al. Genet Med. 2015 Nov;17(11):880-8. doi: 10.1038/gim.2014.205. Epub 2015 Jan 22. Genet Med. 2015. PMID: 25611685 Free article.
PURPOSE: Hypertrophic cardiomyopathy (HCM) is caused primarily by pathogenic variants in genes encoding sarcomere proteins. ...RESULTS: The detection rate is ~32% among unselected probands, with inconclusive results in an additional 15%. Detection rates were …
PURPOSE: Hypertrophic cardiomyopathy (HCM) is caused primarily by pathogenic variants in genes encoding sarcomere proteins. .. …
Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ismayl M, Abbasi MA, Marar R, Geske JB, Gersh BJ, Anavekar NS. Ismayl M, et al. Curr Probl Cardiol. 2023 Jan;48(1):101429. doi: 10.1016/j.cpcardiol.2022.101429. Epub 2022 Sep 24. Curr Probl Cardiol. 2023. PMID: 36167226 Review.
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unchanged for decades until the recent introduction of mavacamten, a first-in-class cardiac myosin inhibitor. ...Secondary outcomes incl …
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has b …
Multi-modality management of hypertrophic cardiomyopathy.
Rao SJ, Iqbal SB, Kanwal AS, Aronow WS, Naidu SS. Rao SJ, et al. Hosp Pract (1995). 2023 Feb;51(1):2-11. doi: 10.1080/21548331.2022.2162297. Epub 2023 Jan 10. Hosp Pract (1995). 2023. PMID: 36598161 Review.
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant inherited condition defined by left ventricular wall thickness greater than 15 mm in the absence of other conditions that could explain that degree of hypertrophy. ...Novel invasive therapies s …
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant inherited condition defined by left ventricular wall thickness grea …
Genetic Testing in Patients with Hypertrophic Cardiomyopathy.
Bonaventura J, Polakova E, Vejtasova V, Veselka J. Bonaventura J, et al. Int J Mol Sci. 2021 Sep 27;22(19):10401. doi: 10.3390/ijms221910401. Int J Mol Sci. 2021. PMID: 34638741 Free PMC article. Review.
Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with an estimated prevalence of up to 1 in 200 individuals. ...
Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with an estimated prevalence of up to 1 in 200 individua …
Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies.
Polovina M, Tschöpe C, Rosano G, Metra M, Crea F, Mullens W, Bauersachs J, Sliwa K, de Boer RA, Farmakis D, Thum T, Corrado D, Bayes-Genis A, Bozkurt B, Filippatos G, Keren A, Skouri H, Moura B, Volterrani M, Abdelhamid M, Ašanin M, Krljanac G, Tomić M, Savarese G, Adamo M, Lopatin Y, Chioncel O, Coats AJS, Seferović PM. Polovina M, et al. Eur J Heart Fail. 2023 Dec;25(12):2144-2163. doi: 10.1002/ejhf.3076. Epub 2023 Nov 14. Eur J Heart Fail. 2023. PMID: 37905371 Review.
Despite improvement in survival with contemporary treatment, SCD remains an important cause of mortality in cardiomyopathies. It occurs at a rate ranging between 0.15% and 0.7% per year (depending on the cardiomyopathy), which significantly surpasses SCD incidence i …
Despite improvement in survival with contemporary treatment, SCD remains an important cause of mortality in cardiomyopathies. It occurs at a …
Usefulness of Genetic Testing in Hypertrophic Cardiomyopathy: an Analysis Using Real-World Data.
Alejandra Restrepo-Cordoba M, Campuzano O, Ripoll-Vera T, Cobo-Marcos M, Mademont-Soler I, Gámez JM, Dominguez F, Gonzalez-Lopez E, Padron-Barthe L, Lara-Pezzi E, Alonso-Pulpon L, Brugada R, Garcia-Pavia P. Alejandra Restrepo-Cordoba M, et al. J Cardiovasc Transl Res. 2017 Feb;10(1):35-46. doi: 10.1007/s12265-017-9730-8. Epub 2017 Jan 30. J Cardiovasc Transl Res. 2017. PMID: 28138913 Review.
This study sought to determine the usefulness of genetic testing to predict evolution in hypertrophic cardiomyopathy (HCM) and to assess the role of genetic testing in clinical practice. ...Only 40 patients (40 %) exhibited PM that had been previously reported and o …
This study sought to determine the usefulness of genetic testing to predict evolution in hypertrophic cardiomyopathy (HCM) and …
Improved Diagnostic Criteria for Apical Hypertrophic Cardiomyopathy.
Hughes RK, Shiwani H, Rosmini S, Augusto JB, Burke L, Jiang Y, Pierce I, Joy G, Castelletti S, Orini M, Kellman P, Xue H, Lopes LR, Mohiddin S, Treibel T, Manisty C, Captur G, Davies R, Moon JC. Hughes RK, et al. JACC Cardiovasc Imaging. 2024 May;17(5):501-512. doi: 10.1016/j.jcmg.2023.07.012. Epub 2023 Oct 11. JACC Cardiovasc Imaging. 2024. PMID: 37831014
BACKGROUND: There is no acceptable maximum wall thickness (MWT) threshold for diagnosing apical hypertrophic cardiomyopathy (ApHCM), with guidelines referring to 15 mm MWT for all hypertrophic cardiomyopathy subtypes. ...A clinically defined dis …
BACKGROUND: There is no acceptable maximum wall thickness (MWT) threshold for diagnosing apical hypertrophic cardiomyopathy (A …
Updates for the diagnosis and management of cardiac amyloidosis.
Gościniak P, Baron T, Milczarek S, Kostkiewicz M, Machaliński B. Gościniak P, et al. Adv Clin Exp Med. 2022 Feb;31(2):175-185. doi: 10.17219/acem/142252. Adv Clin Exp Med. 2022. PMID: 35195962 Free article. Review.
The differential diagnosis of the causes of myocardial hypertrophy includes arterial hypertension, hypertrophic cardiomyopathy, aortic stenosis (AS), athletic heart syndrome, Fabry disease, and cardiac amyloidosis (CA). It turns out that in patients with myocardial …
The differential diagnosis of the causes of myocardial hypertrophy includes arterial hypertension, hypertrophic cardiomyopathy …
Management and outcomes of hypertrophic cardiomyopathy in young adults.
Baron É, Karam N, Donal E, Puscas T, Mirabel M, Bacher A, Wahbi K, Mazzella JM, Jeunemaitre X, Reant P, Hagège A; REMY, GEREMY working groups of the French Society of Cardiology. Baron É, et al. Arch Cardiovasc Dis. 2021 Jun-Jul;114(6-7):465-473. doi: 10.1016/j.acvd.2020.12.006. Epub 2021 Mar 17. Arch Cardiovasc Dis. 2021. PMID: 33744178 Free article.
BACKGROUND: Management of young adults with hypertrophic cardiomyopathy (HCM) is challenging. AIMS: To evaluate the profile of young adults (16-25 years) with HCM included in the French prospective HCM registry. ...RESULTS: At baseline, among 61 patients (20.53.0 ye …
BACKGROUND: Management of young adults with hypertrophic cardiomyopathy (HCM) is challenging. AIMS: To evaluate the profile of …
Genetic Testing in Pediatric Cardiomyopathy.
Ellepola CD, Knight LM, Fischbach P, Deshpande SR. Ellepola CD, et al. Pediatr Cardiol. 2018 Mar;39(3):491-500. doi: 10.1007/s00246-017-1779-2. Epub 2017 Nov 29. Pediatr Cardiol. 2018. PMID: 29188317
Genetic testing is recommended in patients with dilated cardiomyopathy (DCM); however, limited studies demonstrate high yields of genetic testing in non-hypertrophic (HCM) patients. ...Echocardiography revealed mean ejection fraction of 32.4%. The LVEDd z score rang …
Genetic testing is recommended in patients with dilated cardiomyopathy (DCM); however, limited studies demonstrate high yields of gen …
105 results